Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study
Open Access
- 23 March 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (3) , e0161555
Abstract
Environmental factors play a major role on atopic dermatitis (AD) which shows a constant rise in prevalence in western countries over the last decades. The Hygiene Hypothesis suggesting an inverse relationship between incidence of infections and the increase in atopic diseases in these countries, is one of the working hypothesis proposed to explain this trend. This study tested the efficacy and safety of oral administration of the bacterial lysate OM-85 (Broncho-Vaxom®, Broncho-Munal®, Ommunal®, Paxoral®, Vaxoral®), in the treatment of established AD in children. Children aged 6 months to 7 years, with confirmed AD diagnosis, were randomized in a double-blind, placebo-controlled trial to receive, in addition to conventional treatment with emollients and topical corticosteroids, 3.5mg of the bacterial extract OM-85 or placebo daily for 9 months. The primary end-point was the difference between groups in the occurrence of new flares (NF) during the study period, evaluated by Hazard Ratio (HR) derived from conditional Cox proportional hazard regression models accounting for repeated events. Among the 179 randomized children, 170 were analysed, 88 in the OM-85 and 82 in the placebo group. As expected most children in both treatment groups experienced at least 1 NF during the study period (75 (85%) patients in the OM-85 group and 72 (88%) in the placebo group). Patients treated with OM-85 as adjuvant therapy had significantly fewer and delayed NFs (HR of repeated flares = 0.80; 95% confidence interval (CI): 0.67–0.96), also when potential confounding factors, as family history of atopy and corticosteroids use, were taken into account (HR = 0.82; 95% CI: 0.69–0.98). No major side effect was reported, with comparable and good tolerability for OM-85 and placebo. Results show an adjuvant therapeutic effect of a well standardized bacterial lysate OM-85 on established AD.Keywords
This publication has 50 references indexed in Scilit:
- Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhoodJournal of Allergy and Clinical Immunology, 2013
- Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trialTrials, 2013
- The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airwaysMucosal Immunology, 2011
- Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma controlMucosal Immunology, 2010
- Systemic Toll-Like Receptor Stimulation Suppresses Experimental Allergic Asthma and Autoimmune Diabetes in NOD MicePLOS ONE, 2010
- Effect of aMycobacterium vaccaederivative on paediatric atopic dermatitis: a randomized, controlled trialClinical and Experimental Dermatology, 2009
- Effect of Mycobacterium vaccae on atopic dermatitis in children of different agesBritish Journal of Dermatology, 2003
- Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe diseaseJournal of Allergy and Clinical Immunology, 2001
- Survival analysis for recurrent event data: an application to childhood infectious diseasesStatistics in Medicine, 2000
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982